Tamoxifen for men with gynaecomastia is an increasingly recognised off-label treatment option in UK clinical practice. Gynaecomastia — the benign enlargement of glandular breast tissue in males — affects men of all ages and can cause significant physical discomfort and psychological distress. When lifestyle modification or removal of a causative agent proves insufficient, pharmacological intervention may be warranted. Tamoxifen, a selective oestrogen receptor modulator (SERM), works by blocking oestrogen activity within breast tissue, addressing the hormonal imbalance that drives glandular growth. This article outlines how tamoxifen works, its effectiveness, safety considerations, and when to seek further medical advice.

What Is Gynaecomastia and Why Does It Develop in Men

Gynaecomastia is the most common benign breast condition in men, caused by an imbalance between oestrogen and androgen activity in breast tissue, and may result from medications, underlying conditions, or physiological changes.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, resulting in a firm or rubbery swelling beneath one or both nipples. It is distinct from pseudogynaecomastia, which involves fatty tissue accumulation without true glandular proliferation. Although often perceived as uncommon, gynaecomastia is in fact the most frequent benign breast condition in men, affecting males across all age groups.

The underlying cause is an imbalance between oestrogen and androgen activity within breast tissue. Oestrogens stimulate ductal and stromal proliferation, whilst androgens — primarily testosterone — counteract this effect. When this balance tips in favour of oestrogen, glandular growth occurs. This hormonal shift can arise from a variety of causes, including:

• Physiological changes such as puberty, ageing, or neonatal oestrogen exposure

• Medications including anabolic steroids, anti-androgens, spironolactone, digoxin, and certain antipsychotics

• Underlying conditions such as hypogonadism, hyperthyroidism, liver cirrhosis, or testicular tumours

• Recreational drug use, including alcohol; cannabis has been cited as a possible association, though the evidence for a direct causal link remains limited

In many cases, particularly during adolescence, gynaecomastia resolves spontaneously within one to two years. However, when it persists beyond this period or causes significant physical discomfort or psychological distress, medical evaluation and treatment become appropriate.

NICE CKS guidance on gynaecomastia recommends a thorough clinical assessment — including testicular examination — to exclude secondary causes before initiating any pharmacological intervention. A GP will typically arrange blood tests including testosterone, oestradiol, LH, FSH, thyroid function tests (TFTs), prolactin, and liver function. Where a testicular or adrenal tumour is suspected, serum hCG and targeted imaging — such as testicular ultrasound — should also be considered. Renal function may be checked where clinically indicated.

How Tamoxifen Works to Treat Gynaecomastia

Tamoxifen blocks oestrogen receptors in breast tissue without activating them, reducing the oestrogenic signalling that drives glandular growth; it is prescribed off-label in the UK, typically at 10–20 mg daily for up to three months.

Tamoxifen is a selective oestrogen receptor modulator (SERM), a class of medicine that interacts with oestrogen receptors in a tissue-specific manner. In breast tissue, tamoxifen acts as an oestrogen antagonist — it competitively binds to oestrogen receptors, blocking the action of circulating oestrogens and thereby inhibiting the hormonal stimulus responsible for glandular proliferation.

The pharmacological mechanism is particularly relevant in gynaecomastia because the condition is driven by relative or absolute oestrogen excess at the level of breast tissue receptors. By occupying these receptors without activating them, tamoxifen effectively reduces the oestrogenic signalling that promotes ductal growth and stromal expansion. This is why tamoxifen tends to be most effective in the early, active phase of gynaecomastia — when tissue is still predominantly glandular and responsive — rather than in long-standing cases where fibrous replacement has already occurred.

It is important to note that tamoxifen is not licensed by the MHRA specifically for the treatment of gynaecomastia in men. Its use in this context is therefore considered off-label, meaning it is prescribed outside its formally approved indications (which include breast cancer treatment and prevention in high-risk individuals). Off-label prescribing is legally permissible in the UK when a clinician determines it is in the patient's best interest and is supported by a reasonable body of clinical evidence. Patients should be informed of the off-label status and give appropriate consent, with this documented in the clinical record.

In line with NICE CKS guidance and the BNF, tamoxifen for gynaecomastia is typically prescribed at 10 mg twice daily (or 20 mg once daily) for up to three months, with clinical reassessment at that point. Continuation beyond three months should only be considered if there is clear evidence of benefit and after a careful review of risks. Prescribers should refer to the current BNF and MHRA/emc Summary of Product Characteristics (SmPC) for full prescribing information.

Effectiveness of Tamoxifen for Male Breast Tissue Reduction

Tamoxifen produces meaningful breast tissue reduction in a substantial proportion of men with recent-onset gynaecomastia, with smaller studies reporting response rates of 60–80%, though large randomised controlled trials are lacking.

The clinical evidence supporting tamoxifen for gynaecomastia is reasonably consistent across multiple smaller studies and case series, though it is important to note that large-scale randomised controlled trials are lacking. Systematic reviews of medical therapy for gynaecomastia (including Fagerlund et al., 2015) suggest that tamoxifen produces meaningful reductions in breast tissue volume in a substantial proportion of men with recent-onset gynaecomastia, with response rates in smaller studies generally reported in the range of 60–80%. However, these figures should be interpreted cautiously given the heterogeneity of study populations, varying definitions of response, and small sample sizes.

Comparative studies have evaluated tamoxifen against other agents such as danazol and raloxifene. Tamoxifen has generally demonstrated a more favourable tolerability profile than danazol, which carries a higher risk of androgenic side effects. When compared with raloxifene — another SERM — results have been variable, and no definitive superiority has been established for either agent in adults.

Key factors influencing treatment response include:

• Duration of gynaecomastia: Tissue present for less than 12 months responds significantly better than long-standing, fibrotic disease

• Underlying cause: Addressing a reversible cause (e.g., stopping a causative medication) alongside tamoxifen may improve outcomes

• Dose and duration: Most evidence uses 10–20 mg daily for up to three months, with reassessment before any extension

Complete resolution is not guaranteed, and some residual tissue may persist even after a successful course. Recurrence following cessation of treatment has been reported and patients should be counselled accordingly. In cases where pharmacological treatment fails or where gynaecomastia has been present for more than 12 months with established fibrosis, surgical referral for subcutaneous mastectomy may be the most appropriate next step.

Side Effects and Safety Considerations for Men

Tamoxifen is generally well tolerated in men, but carries clinically important risks including thromboembolic events, ocular effects with prolonged use, and significant potentiation of coumarin anticoagulants such as warfarin.

Tamoxifen is generally well tolerated in men, though patients should be counselled about potential adverse effects before commencing treatment. The side effect profile in males is broadly similar to that observed in women, although some effects — such as hot flushes and mood changes — may be less frequently reported in men.

Common side effects include:

• Hot flushes and sweating

• Reduced libido or sexual dysfunction

• Mood changes, including low mood or irritability

• Nausea or mild gastrointestinal upset

• Headache

Less common but clinically important risks include:

• Thromboembolic events: Tamoxifen increases the risk of deep vein thrombosis (DVT) and pulmonary embolism. Men with pre-existing risk factors — such as obesity, immobility, or a personal or family history of clotting disorders — should be assessed carefully before prescribing. In line with SmPC guidance, consideration should be given to interrupting tamoxifen before elective major surgery or during periods of prolonged immobility, restarting only once the patient is fully mobile

• Ocular effects: Prolonged use has been associated with retinal changes and cataracts; ophthalmological review may be warranted in long-term users

• Hepatic effects: Rare cases of hepatotoxicity have been reported. Routine liver function monitoring is not required for all patients on short courses; however, baseline testing and monitoring should be considered in those with pre-existing hepatic risk factors or if symptoms suggestive of liver dysfunction arise

From a safety perspective, tamoxifen should be used with caution in men with a history of thromboembolic disease or hepatic impairment. In men taking coumarin anticoagulants such as warfarin, tamoxifen can significantly potentiate anticoagulant effects; close INR monitoring and specialist advice are required, and the combination should be avoided where possible.

The MHRA advises that prescribers remain vigilant for interactions with strong CYP2D6 inhibitors — such as paroxetine and fluoxetine — which can reduce tamoxifen's conversion to its active metabolite, endoxifen. Where feasible, alternative agents should be considered; if co-prescription is unavoidable, the potential impact on efficacy should be discussed with the patient.

Patients should be encouraged to report any new or worsening symptoms promptly during treatment. Suspected adverse drug reactions should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

When to Seek Medical Advice and Alternative Treatment Options

Men with breast swelling, hard or irregular lumps, or nipple changes should seek prompt medical evaluation to exclude male breast cancer; urgent referral via the two-week wait pathway should be considered for men aged 50 and over with a unilateral firm subareolar mass.

Men who notice breast swelling, tenderness, or nipple discharge should seek prompt medical evaluation rather than self-treating. Whilst gynaecomastia is most commonly benign, male breast cancer — though rare, accounting for less than 1% of all breast cancers — must be excluded. Features that warrant urgent referral include a hard, irregular, or asymmetrical lump, skin changes, nipple retraction, or associated lymphadenopathy.

NICE guidance on suspected cancer (NG12) advises clinicians to consider a suspected cancer pathway referral (two-week wait) for men aged 50 and over with a unilateral, firm subareolar mass with or without nipple changes. Men below this age threshold with atypical or concerning features should still be referred promptly according to clinical judgement.

For men already receiving tamoxifen, the following symptoms require urgent action:

• Leg pain, swelling, or redness — possible DVT: seek urgent medical assessment (contact 111 or attend A&E if symptoms are severe or rapidly worsening)

• Sudden breathlessness or chest pain — possible pulmonary embolism: call 999 immediately

• Visual disturbances — possible ocular toxicity: contact a GP or seek same-day advice

• Unexplained jaundice or abdominal pain — possible hepatic effects: contact a GP promptly

Where tamoxifen is not suitable or has been ineffective, several alternative approaches exist. Raloxifene, another SERM, has shown some efficacy in smaller studies and may be considered as an alternative off-label option, though evidence in adult men remains limited. Danazol, a synthetic androgen, has been used historically but is associated with more significant androgenic side effects and is less commonly prescribed today. Aromatase inhibitors such as anastrozole have been investigated, particularly in adolescents, but evidence supporting their use in adult men is limited and they are not routinely recommended outside specialist settings.

For persistent or fibrotic gynaecomastia unresponsive to medical therapy, surgical intervention — typically subcutaneous mastectomy or liposuction-assisted excision — offers a definitive solution. NHS funding for surgery varies by locality and is generally considered where significant psychological or physical impact is demonstrated; clinicians should follow local referral and commissioning pathways. Referral to an endocrinologist or breast surgeon may be appropriate depending on the clinical picture.

Frequently Asked Questions